Fenestrated Endografts as Treatment for Type I Endoleak: What is the Price of Success?

Both fenestrated and branched endografts are effective to treat patients after failure of their initial endograft due to significant type I endoleak. This situation is costly both because of the devices themselves, and also due to the several endovascular and surgical procedures required.

Prótesis fenestradas para tratar endoleak tipo 1 ¿cuál es el precio del éxito?

Failure of an endograft to treat an infrarenal abdominal aortic aneurysm due to the development of a type Ia endoleak exposes patients to pressurization of the sac, which may cause a rupture. Type I endoleaks must undoubtedly be treated—unlike type II endoleaks, around which controversy may arise.

The purpose of this study was to evaluate the results of fenestrated/branched grafts for the treatment of type Ia endoleaks.

Between 2010 and 2019, 85 consecutive patients who received a fenestrated/branched graft after failure of a conventional prosthesis were included. The primary endpoint was freedom from re-intervention and death related to the procedure.

In 30 cases (35%), the initial prosthesis was implanted in a hostile neck—either too short (<10mm) or angled (>60°). Less frequent reasons were poor placement of the initial prosthesis, sizing error, or stent migration. 

Type Ia endoleaks were observed 59 ± 25 months following implantation of the initial prosthesis. As a solution, 82 fenestrated grafts and 3 branched grafts were used. Overall technical success was 94%, with one persistent type Ia endoleak, and two unsuccessful stent graft implantations.

In-hospital mortality rate was 5%, and the most feared complication in this type of procedure—spinal cord ischemia—occurred in four patients.


Read also: SOLACI PERIPHERAL | Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection.


At three years, the survival rate was 64% with an overall freedom from any re-intervention or aneurysm-related death of 40%. However, the secondary patency rate of the target visceral arteries was 96%.

Despite all efforts, six patients had to undergo conventional surgery.

Conclusion

Fenestrated/branched grafts are an effective treatment when conventional prostheses fail due to type 1A endoleak, although re-interventions and device costs can be high.

Original title: Prospective Multicentre Cohort Study of Fenestrated and Branched Endografts After Failed Endovascular Infrarenal Aortic Aneurysm Repair with Type Ia Endoleak.

Reference: Aurélien Hostalrich et al. Eur J Vasc Endovasc Surg. 2021 Aug 4;S1078-5884(21)00525-6. Online ahead of print. doi: 10.1016/j.ejvs.2021.06.019. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...